Oxford Immunotec (OXFD) Enters MOU with GC MS to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea.
Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit.
Based on the Company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is already available for research use across Europe and the USA. Study data recently released by Public Health England1 using the T-SPOT Discovery SARS-CoV-2 kit suggests that individuals with a SARS-CoV-2 specific T cell response, but without detectible antibodies (serology), may be protected from infection. Therefore, measuring the T cell response to SARS-CoV-2 may be an important adjunct to serological analysis.
GC MS is an industry leader in the field of medical devices and diagnostic reagents, and a member of the GC Pharmaceutical companies, in South Korea. They already carry six diagnostic tests for COVID-19, and are committed to offering a full range of diagnosis/treatment methods by way of diverse testing techniques, including PCR tests, antigen tests and antibody tests. T-SPOT Discovery SARS-CoV-2 will enable them to add a research test to measure the T cell response to SARS-CoV-2 infection to their offering. The test is currently being used in studies in the UK for COVID-19 vaccine development and for clinical evaluation.
Walt Ling, VP commercial APAC for Oxford Immunotec said, “We are delighted to work in partnership with GC MS. This MOU means that the T-SPOT Discovery SARS-CoV-2 kit will be available to more researchers and multiple biopharmaceutical companies that are developing innovative treatments and vaccines across South Korea, which we believe will make a significant contribution towards informing how we can better manage the ongoing pandemic in the country.”
T-SPOT Discovery SARS-CoV-2 is for research use only, not for use in diagnostic procedures.
Not all products are available in all regions, please contact us for information on availability in any specific country.
1 To view the PHE publication, visit: https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1.
For further information on T-SPOT Discovery SARS-CoV-2, visit: https://www.tspotdiscovery.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anaptysbio (ANAB) Announces FDA Approves JEMPERLI for dMMR Endometrial Cancer
- APi Group Corporation (APG) Announces Goal of Over 13% Adjusted EBITDA Margin by Year-End 2025
- Quidel Corp (QDEL) Prelim. Q1 Revenue Misses Consensus
Create E-mail Alert Related CategoriesCorporate News
Related EntitiesS3, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!